一名男性接种Ad26.COV2.S疫苗后出现疫苗诱导的免疫性血栓性血小板减少症，表现为脑静脉窦血栓形成。
Vaccine-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis.
作者信息
Wu James Fan, Bajwa Umair, Hammad Muhammad
机构信息
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
出版信息
Platelets. 2022 Jul 4;33(5):797-800. doi: 10.1080/09537104.2022.2071854. Epub 2022 May 9.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and life-threatening complication that can occur after COVID-19 vaccination. After the first reports of VITT and CVST in 2021 after Ad26.COV2.S vaccination, the FDA and CDC recommended an emergency pause on 13 April 2021, and after extensive safety reviews, on 23 April 2021, the CDC's Advisory Committee on Immunization Practices (ACIP) reaffirmed its original recommendation for use of the Ad26.COV2.S vaccination. As of 31 August 2021, in the United States, 54 cases of VITT following Ad26.COV2.S vaccination (37 female, 17 male) have been reported out of 14.1 million total shots given, 29 of which had cerebral venous sinus thrombosis (CVST). With more data, on 16 December 2021, the CDC endorsed the ACIP recommendations for individuals to receive an mRNA COVID-19 vaccine in preference over the Ad26.COV2.S vaccination. We report a rare case of a male with confirmed VITT and CVST following Ad26.COV2.S vaccination.
疫苗诱导的免疫性血栓性血小板减少症（VITT）是一种在接种新冠疫苗后可能出现的罕见且危及生命的并发症。在2021年首次报告接种Ad26.COV2.S疫苗后出现VITT和脑静脉窦血栓形成（CVST）后，美国食品药品监督管理局（FDA）和疾病控制与预防中心（CDC）于2021年4月13日建议紧急暂停使用该疫苗。经过广泛的安全性审查后，2021年4月23日，CDC的免疫实践咨询委员会（ACIP）重申了其关于使用Ad26.COV2.S疫苗的最初建议。截至2021年8月31日，在美国，在总共接种的1410万剂Ad26.COV2.S疫苗中，报告了54例接种后出现VITT的病例（37例女性，17例男性），其中29例伴有脑静脉窦血栓形成（CVST）。随着更多数据的出现，2021年12月16日，CDC认可了ACIP的建议，即个人优先接种mRNA新冠疫苗而非Ad26.COV2.S疫苗。我们报告了一例接种Ad26.COV2.S疫苗后确诊为VITT并伴有CVST的罕见男性病例。
Zotero 插件